No. 18-1280

Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., et al.

Lower Court: Federal Circuit
Docketed: 2019-04-08
Status: Denied
Type: Paid
Amici (5) Experienced Counsel
Tags: blocking-patent-doctrine blocking-patents burden-of-proof graham-v-john-deere nonobviousness objective-indicia obviousness patent patent-law patent-obviousness pharmaceutical-innovation prior-art
Key Terms:
Patent
Latest Conference: 2019-10-01
Question Presented (AI Summary)

Whether objective indicia of nonobviousness may be partially or entirely discounted where the development of the invention was allegedly 'blocked' by the existence of a prior patent, and, if so, whether an 'implicit finding' that an invention was 'blocked,' without a finding of actual blocking, is sufficient to conclude that an infringer has met its burden of proof

Question Presented (OCR Extract)

QUESTION PRESENTED Under 35 U.S.C. § 103, a patent “may not be obtained ... if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious... toa person having ordinary skill in the art.” In Graham v. John Deere Co., 383 U.S. 1 (1966), this Court explained that the obviousness inquiry should encompass objective “indicia” of nonobviousness such as “commercial success, long felt but unsolved needs, [and] failure of others,” id. at 17-18. In the decision below, however, a divided panel of the Federal Circuit discounted what the district court deemed to be Acorda’s “significant” and “convincing” evidence of nonobviousness because the claimed invention—the first drug for treating walking in patients with multiple sclerosis—built on a prior patent licensed to Acorda that supposedly “blocked” other companies from developing the claimed methods. According to the Federal Circuit, the defendants had met their burden of proving obviousness by clear and convincing evidence because Acorda had not “suppllied]” its own “evidence to make unreasonable” the district court’s “implicit finding” that “securing freedom from blocking patents ... is likely important to pharmaceutical research.” The question presented is whether objective indicia of nonobviousness may be partially or entirely discounted where the development of the invention was allegedly “blocked” by the existence of a prior patent, and, if so, whether an “implicit finding” that an invention was “blocked,” without a finding of actual blocking, is sufficient to conclude that an infringer has met its burden of proof.

Docket Entries

2019-10-07
Petition DENIED.
2019-06-26
DISTRIBUTED for Conference of 10/1/2019.
2019-06-25
Reply of petitioner Acorda Therapeutics, Inc. filed.
2019-06-07
Brief of respondents Mylan Pharmaceuticals Inc., et al. in opposition filed.
2019-05-08
Brief amicus curiae of Pharmaceutical Research and Manufacturers of America filed.
2019-05-08
Brief amici curiae of Allergan, Inc., et al. filed.
2019-05-08
Brief amicus curiae of Biotechnology Innovation Organization filed.
2019-05-08
Brief amicus curiae of Boston Patent Law Association filed.
2019-05-06
Motion to extend the time to file a response is granted and the time is extended to and including June 7, 2019, for all respondents.
2019-05-06
Brief amicus curiae of Intellectual Property Owners Association in support of neither party filed.
2019-05-01
Motion to extend the time to file a response from May 8, 2019 to June 7, 2019, submitted to The Clerk.
2019-04-04
Petition for a writ of certiorari filed. (Response due May 8, 2019)

Attorneys

Acorda Therapeutics, Inc.
Theodore B. OlsonGibson Dunn & Crutcher LLP, Petitioner
Allergan, Inc., Helsinn Healthcare S.A., Breas Medical AB, Akebia Therapeutics, Inc., Ironwood Pharmaceuticals, Inc., Adamas Pharmaceuticals, Inc.
Sarah Michelle HarrisWilliams & Connolly LLP, Amicus
Biotechnology Innovation Organization
Charles Edmund LipseyFinnegan Henderson Farabow Garrett and Dunner, Amicus
Boston Patent Law Association
Sophie Feifei WangChoate Hall & Stewart LLP, Amicus
INTELLECTUAL PROPERTY OWNERS ASSOCIATION
Paul H. BerghoffMcDonnell Boehnen Hulbert & Berghoff, LLP, Amicus
Mylan Pharmaceuticals Inc.
Dan L. BagatellPerkins Coie LLP, Respondent
Pharmaceutical Research and Manufacturers of America
Beth Susan BrinkmannCovington & Burling, Amicus
Roxane Laboratories, Inc., and Teva Pharmaceuticals USA, Inc.
Charles Bennett KleinWinston & Strawn LLP, Respondent